Fulvestrant monotherapy is not listed under “Preferred Regimens” but is classified as an “Other Recommended Regimen” for first- and/or subsequent-line therapy in HR+/HER2- advanced breast cancer, according to current guidelines [2]. Here, ERBB2 is linked to breast carcinoma.